Transcenta Holding Limited (HK:6628) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Transcenta Holding Limited has reported promising Phase II results for Osemitamab (TST001) in combination with Nivolumab and CAPOX as a first-line treatment for advanced gastric or gastroesophageal cancer, showing a median progression-free survival of 12.6 months in patients with certain biomarkers. These findings, which will be presented at ASCO 2024, could potentially improve the standard of care for HER2-negative metastatic gastric cancer patients, particularly those with lower PD-L1 expression.
For further insights into HK:6628 stock, check out TipRanks’ Stock Analysis page.